Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5827260 | European Journal of Pharmacology | 2015 | 11 Pages |
Abstract
In this manuscript we review the connections in the triangle between nonclinical efficacy/safety studies and regulatory aspects, with focus on in vivo testing of drugs. These connections differ for different drugs (chemistry-based low molecular weight compounds, recombinant proteins, cell therapy or gene therapy products). Regarding animal models and their translational value we focus on regulatory aspects and indications where scientific outcomes warrant changes, reduction or replacement, like for, e.g., biosimilar evaluation and safety testing of monoclonal antibodies. On the other hand, we present applications where translational value has been clearly demonstrated, e.g., immunosuppressives in transplantation. Especially for drugs of more recent date like recombinant proteins, cell therapy products and gene therapy products, a regulatory approach that allows the possibility to conduct combined efficacy/safety testing in validated animal models should strengthen scientific outcomes and improve translational value, while reducing the numbers of animals necessary.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Peter J.K. van Meer, Melanie L. Graham, Henk-Jan Schuurman,